**PRODUCT:** AT-7519 hydrochloride

**ALTERNATE NAME:** N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide hydrochloride

**CATALOG #:** 2816-5, 25

**AMOUNT:** 5 mg, 25 mg

**STRUCTURE:**

<table>
<thead>
<tr>
<th>MOLECULAR FORMULA:</th>
<th>C₁₆H₁₈Cl₃N₅O₂</th>
</tr>
</thead>
<tbody>
<tr>
<td>MOLECULAR WEIGHT:</td>
<td>418.71</td>
</tr>
<tr>
<td>CAS NUMBER:</td>
<td>902135-91-5</td>
</tr>
<tr>
<td>APPEARANCE:</td>
<td>White solid</td>
</tr>
<tr>
<td>SOLUBILITY:</td>
<td>DMSO</td>
</tr>
<tr>
<td>PURITY:</td>
<td>≥98% by HPLC</td>
</tr>
</tbody>
</table>

**DESCRIPTION:**
AT-7519 is a potent CDK inhibitor with potential antineoplastic activity. AT-7519 displays potent antiproliferative activity (40-940 nM) in a panel of human tumor cell lines, and the mechanism of action is shown to be consistent with the inhibition of CDK1 and CDK2 in solid tumor cell lines. AT-7519 causes cell cycle arrest followed by apoptosis in human tumor cells and inhibits tumor growth in human tumor xenograft models.

**REFERENCES:**

**HANDLING:**
Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**USAGE:**
*FOR RESEARCH CH USE ONLY! Not to be used in humans*

**RELATED PRODUCTS:**
- Alsterpaullone (Cat. No. 1897-1,5)
- Butyrolactone I (Cat. No. 1690-200)
- Doramapimod (Cat. No. 1954-5, 25)
- Flavopiridol (Cat. No. 2090-1, 5)
- Kenpaullone (Cat. No. 1904-1)
- PD1834352 (CI-1040) (Cat. No. 1585-1,5,25)
- EZSolution™ PD184352 (Cat. No. 1871-1)
- PD325901 (Cat. No. 1643-2, 5, 25)
- PD98059 (Cat. No. 1666-5)
- EZSolution™ PD98059 (Cat. No. 1783-5)
- (R)-Perharidine-1 (Cat. No. 2615-1,5)
- RO-3306 (Cat. No. 2039-1,5)
- Roscovitine (Cat. No. 1950-1,5)
- SB 203580 (Cat. No. 1712-1, 5)
- EZSolution™ SB203580 (1786-1)
- Sorafenib (Cat. No. 1594-25, 100)
- TG003 (Cat. No. 1905-5, 25)
- 7, 3', 4'-Trihydroxyisoflavone (1886-25, 100)
- U0126 (Cat. No. 1668-5)
- VX-702 (Cat. No. 1598-1,5)